{"id":32724,"date":"2025-04-30T11:25:56","date_gmt":"2025-04-30T03:25:56","guid":{"rendered":"https:\/\/flcube.com\/?p=32724"},"modified":"2025-04-30T11:25:56","modified_gmt":"2025-04-30T03:25:56","slug":"astrazenecas-q1-2025-results-10-revenue-growth-oncology-segment-shines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32724","title":{"rendered":"AstraZeneca&#8217;s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines"},"content":{"rendered":"\n<p>UK-based AstraZeneca (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ: AZN<\/a>) released its Q1 2025 financial results, showing a 10% year-on-year (YOY) increase in total revenues to USD 13.59 billion in constant currency terms. Product sales grew by 9% YOY to USD 12.88 billion, while alliance revenues surged by 42% to USD 639 million. Guidance for the year remains unchanged.<\/p>\n\n\n\n<p><strong>Segment Performance<\/strong><br>The oncology segment grew by 13% to USD 5.64 billion, while biopharmaceuticals increased by 12% to USD 5.63 billion. Key product sales included:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Farxiga (dapagliflozin) for type 2 diabetes: USD 2.06 billion, +16%<\/li>\n\n\n\n<li>Tagrisso (osimertinib) for lung cancer: USD 1.68 billion, +8%<\/li>\n\n\n\n<li>PD-L1 inhibitor Imfinzi (durvalumab): USD 1.26 billion, +16%<\/li>\n\n\n\n<li>BTK inhibitor Calquence (acalabrutinib): USD 762 million, +8%<\/li>\n\n\n\n<li>Enhertu (trastuzumab deruxtecan): USD 596 million, +34%<\/li>\n\n\n\n<li>PARP inhibitor Lynparza (olaparib): USD 726 million, +5%<\/li>\n<\/ul>\n\n\n\n<p><strong>R&amp;D Highlights<\/strong><br>CEO Pascal Soriot highlighted five positive Phase III studies reported this year, including two new molecular entities (NMEs): camizestrant, an oral selective estrogen receptor degrader (SERD) and complete ER antagonist, which hit endpoints for HR-positive, HER2-negative advanced breast cancer in combination with a CDK4\/6 inhibitor; and eneboparatide, a parathyroid hormone receptor 1 agonist, which produced positive data in adults with chronic hypoparathyroidism. Soriot also announced the establishment of an R&amp;D center in Beijing, China, the company&#8217;s second global-level R&amp;D center after Shanghai and its sixth globally.<\/p>\n\n\n\n<p><strong>Regional Performance<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Location<\/th><th>Q1 Sales (USD mil.)<\/th><th>% of Total<\/th><th>Growth (%)<\/th><\/tr><\/thead><tbody><tr><td>US<\/td><td>5,646<\/td><td>42<\/td><td>10<\/td><\/tr><tr><td>Emerging markets ex. China<\/td><td>2,138<\/td><td>16<\/td><td>17<\/td><\/tr><tr><td>China<\/td><td>1,805<\/td><td>13<\/td><td>5<\/td><\/tr><tr><td>Europe<\/td><td>2,759<\/td><td>20<\/td><td>9<\/td><\/tr><tr><td>Established ROW<\/td><td>1,239<\/td><td>9<\/td><td>9<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Source: AstraZeneca<\/p>\n\n\n\n<p><strong>China Market Specifics<\/strong><br>AstraZeneca expects headwinds later this year as Farxiga and roxadustat are included in China\u2019s volume-based procurement (VBP) program. Falling sales of asthma and COPD drug Symbicort (budesonide, formoterol fumarate) were mainly due to decreased demand in the China market, but this was offset by the triple-acting COPD drug Breztri (budesonide, glycopyrrolate, formoterol fumarate) gaining a market-leading share. Other growth drivers in China included Imfinzi for gastrointestinal cancer and Zoladex (goserelin) for breast and prostate cancer.<\/p>\n\n\n\n<p><strong>Investigations in China<\/strong><br>The investigations into AstraZeneca over illegal importation of cancer drugs and misuse of patient data in Guangdong province appear to be concluding without significant fallout. The company owes USD 1.6 million in importation taxes for Enhertu and may face a fine of up to USD 8 million. The case regarding alleged personal information infringement has been transferred to the prosecutor in Shenzhen, but the company has been informed there were no illegal gains from any alleged infringement.<\/p>\n\n\n\n<p><strong>Preparedness for Tariffs<\/strong><br>CEO Pascal Soriot reassured investors during the earnings conference call regarding AstraZeneca\u2019s preparedness for potential tariffs from the US administration. The company&#8217;s global production network includes 31 sites, with 11 in the US. AstraZeneca has committed to investing an additional USD 3.5 billion in the US market by the end of 2026. Soriot noted that any impact from tariffs would be manageable within the company&#8217;s global network.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/Q1-2025-results-presentation.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Q1-2025-results-presentation.\"><\/object><a id=\"wp-block-file--media-500310af-040f-49e4-a799-45c0a60102a5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/Q1-2025-results-presentation.pdf\">Q1-2025-results-presentation<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/Q1-2025-results-presentation.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-500310af-040f-49e4-a799-45c0a60102a5\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/Q1-2025-results-announcement.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Q1-2025-results-announcement.\"><\/object><a id=\"wp-block-file--media-94857e49-0bcd-48a2-a48f-7153718e7356\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/Q1-2025-results-announcement.pdf\">Q1-2025-results-announcement<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32727,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,16,39,20,27,83,871,767,18],"class_list":["post-32724","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-astrazeneca","tag-cancer","tag-diabetes","tag-finance","tag-finanical-reports","tag-her2","tag-nasdaq-azn","tag-parp","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca&#039;s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY) increase in total revenues to USD 13.59 billion in constant currency terms. Product sales grew by 9% YOY to USD 12.88 billion, while alliance revenues surged by 42% to USD 639 million. Guidance for the year remains unchanged.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32724\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca&#039;s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines\" \/>\n<meta property=\"og:description\" content=\"UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY) increase in total revenues to USD 13.59 billion in constant currency terms. Product sales grew by 9% YOY to USD 12.88 billion, while alliance revenues surged by 42% to USD 639 million. Guidance for the year remains unchanged.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32724\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-30T03:25:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca&#8217;s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines\",\"datePublished\":\"2025-04-30T03:25:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724\"},\"wordCount\":466,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3002.webp\",\"keywords\":[\"AstraZeneca\",\"Cancer\",\"Diabetes\",\"Finance\",\"Finanical Reports\",\"HER2\",\"NASDAQ: AZN\",\"PARP\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32724#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32724\",\"name\":\"AstraZeneca's Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3002.webp\",\"datePublished\":\"2025-04-30T03:25:56+00:00\",\"description\":\"UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY) increase in total revenues to USD 13.59 billion in constant currency terms. Product sales grew by 9% YOY to USD 12.88 billion, while alliance revenues surged by 42% to USD 639 million. Guidance for the year remains unchanged.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32724\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3002.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca's Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32724#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca&#8217;s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines - Insight, China&#039;s Pharmaceutical Industry","description":"UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY) increase in total revenues to USD 13.59 billion in constant currency terms. Product sales grew by 9% YOY to USD 12.88 billion, while alliance revenues surged by 42% to USD 639 million. Guidance for the year remains unchanged.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32724","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines","og_description":"UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY) increase in total revenues to USD 13.59 billion in constant currency terms. Product sales grew by 9% YOY to USD 12.88 billion, while alliance revenues surged by 42% to USD 639 million. Guidance for the year remains unchanged.","og_url":"https:\/\/flcube.com\/?p=32724","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-30T03:25:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32724#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32724"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca&#8217;s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines","datePublished":"2025-04-30T03:25:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32724"},"wordCount":466,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32724#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3002.webp","keywords":["AstraZeneca","Cancer","Diabetes","Finance","Finanical Reports","HER2","NASDAQ: AZN","PARP","PD-1\/L1"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32724#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32724","url":"https:\/\/flcube.com\/?p=32724","name":"AstraZeneca's Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32724#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32724#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3002.webp","datePublished":"2025-04-30T03:25:56+00:00","description":"UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY) increase in total revenues to USD 13.59 billion in constant currency terms. Product sales grew by 9% YOY to USD 12.88 billion, while alliance revenues surged by 42% to USD 639 million. Guidance for the year remains unchanged.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32724#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32724"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32724#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3002.webp","width":1080,"height":608,"caption":"AstraZeneca's Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32724#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca&#8217;s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32724"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32724\/revisions"}],"predecessor-version":[{"id":32728,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32724\/revisions\/32728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32727"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}